Study Name:
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
Evaluate safety, tolerability, and pharmacokinetics of ZL-1310 in subjects with small cell lung cancer.
Study Dates:
January 1, 2024 - July 30, 2027
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Zai Lab
ClinicalTrails.gov Identifier:
NCT06179069
